A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

This study tests a new drug called F182112 in people with multiple myeloma — a type of blood cancer affecting plasma cells — whose cancer has come back or stopped responding to previous treatments. The study is particularly for those who have already received lenalidomide and a proteasome inhibitor. **You may be eligible if...** - You have confirmed multiple myeloma - Your previous treatment included both lenalidomide (for at least 2 cycles) and a proteasome inhibitor - Your cancer is measurable via blood or urine tests - Your overall health (ECOG 0–2) allows participation **You may NOT be eligible if...** - Your previous treatment included pomalidomide or you could not tolerate it - Your multiple myeloma has not returned or is not active - You have serious organ problems Talk to your doctor to see if this trial is right for you.